Overview
Biologics and Immune Therapies in an Office Setting – Optimizing Treatment and Outcomes through Patient-centered Care - Non-CME
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Dr. Gregory Bensch, Dr. Bradley Chipps, and Dr. Joshua Jacobs facilitate an interactive discussion of injectable and infused therapies in the pulmonary, allergy, immunology and thoracic settings and their roles in treatment. Patient-centered benefits of office-based administration and operational strategies for establishing an in-office infusion practice will be highlighted throughout this activity via case studies and a collaborative panel discussion. These benefits can be found in an online, step-by-step practice setup guide developed to assist those looking to establish in office infusions www.officeinfusions.com
This educational activity is intended for clinicians considering in-office administration of biologics and immunotherapies including allergists, pulmonologists, immunologists, thoracic surgeons, and other clinicians.
Better understanding of the pathophysiology and phenotypes associated with asthma has led to new therapies which offer patients personalized approaches to disease control. Use of these therapies in clinical practice may require clinicians to retool their practice. This activity will compare and contrast IV and subcutaneous therapies for moderate-severe emphysema and asthma which are not well-controlled by other means. Additionally, an overview of how to utilize these therapies clinically, including the methodology needed to establish in-office infusions will also be discussed, affording clinicians an opportunity to realize how new treatments may be employed in order to maximize patient outcomes.
Upon completion of this activity, participants will be able to:
- Outline the merits of establishing office-based administration of therapies.
- Discuss steps required to establish office-based infusion services.
This activity is supported by an educational grant from Teva Pharmaceuticals.
Gregory Bensch, MD
Stockton, CA
Stockton, CA
Bradley Chipps, MD
Sacramento, CA
Josh Jacobs, MD
Walnut Creek, CA
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this activity.
The following financial relationships have been provided:
Gregory Bensch, MD
Advisory Board & Speakers’ Bureau: AstraZeneca, Teva Pharmaceuticals
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
Bradley E. Chipps, MD
Consulting Agreements, Speakers’ Bureau & Honorarium recipient: AstraZeneca, Boehringer Ingelheim, Circassia, Genentech/Novartis, Teva Pharmaceuticals
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
Joshua S. Jacobs, MD
Sources of Funding for Research Grants: AstraZeneca, CSL Behring, Genentech, Shire, Teva Pharmaceuticals
Advisory Board & Speakers’ Bureau: AstraZeneca, CSL Behring, Shire, Teva Pharmaceuticals
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Participants are required to complete the pre-test, view the online activity, complete the post-test and evaluation.